NCT07243171
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
At risk: Primary completion moved at least 5 months later.
See at-risk trials from Hangzhou Sciwind Biosciences Co., Ltd.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Interventions modified
- Notable Enrollment increased: 84 → 126 participants
- Eligibility criteria expanded, about 9 words
- Secondary endpoints: details revised at 1 of 10 entries
- Study description expanded, about 3 words
- Minor Primary completion pushed from Aug 3, 2026 to Jan 5, 2027
- Study completion pushed from Nov 22, 2026 to Apr 28, 2027
- Site contact updated
- Minor Site details revisedv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria shortened, about 4 words
- Start date changed from estimate of Nov 17, 2025 to Nov 18, 2025
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (10)
Show 5 moreShow less
Arms and interventions
once daily, up-titration every 7 days, dosing for 21 days in total
once daily, up-titration every 7 days, dosing for 28 days in total
once weekly, up-titration every 2-4 weeks, dosing for 24 weeks in total
once weekly, up-titration every 2-4 weeks, dosing for 24 weeks in total
once weekly, up-titration every 4 weeks, dosing for 24 weeks in total
once daily, up-titration every 7 days, dosing for 28 days in total
Drugs: ecnoglutide tablets, placebo with matching dosage
Sites
1 site in 1 country
- China-Japan Friendship HospitalBeijing, Beijing Municipality, China